5-MeO-MiPT

{{Short description|Chemical compound}} {{cs1 config|name-list-style=vanc|display-authors=6}} {{Infobox drug | Verifiedfields = verified | Watchedfields = verified | verifiedrevid = 477224982 | image = 5-MeO-MiPT.svg | width = 250px | image_class = skin-invert-image | image2 = 5-MeO-MiPT 3D.png | image_class2 = bg-transparent | width2 = 250px

| legal_AU = | legal_BR = F2 | legal_BR_comment = <ref>{{Cite web | author = Anvisa | author-link=Brazilian Health Regulatory Agency | title = RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial | date = 2023-07-24 | trans-title = Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control | url = https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 | url-status = live | archive-url = https://web.archive.org/web/20230827163149/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 | archive-date = 2023-08-27 | access-date = 2023-08-27 | publisher = Diário Oficial da União | language = pt-BR | publication-date = 2023-07-25 }}</ref> | legal_CA = | legal_UK = Class A | legal_US = | legal_status =

| bioavailability = | protein_bound = | metabolism = CYP2D6<ref name="Krol2026" /> | onset = Oral: 30 min (15–45 min)<ref name="TiHKAL" /><ref name="Mullin_2025" /><ref name="Krol2026" /> Oral, peak: 1–3 hours<ref name="TiHKAL" /><ref name="Mullin_2025" /><ref name="Krol2026" /> | elimination_half-life = ~2–3 hours<ref name="Krol2026" /> | duration_of_action = Oral: 4–6 hours<ref name="TiHKAL" /><ref name="Krol2026" /> or 3–8 hours<ref name="Aragon_2024" /><ref name="Malaca_2020" /> Smoked: 2–5 hours<ref name="Aipsin" /> | excretion =

| CAS_number_Ref = {{cascite|correct|CAS}} | CAS_number = 96096-55-8 | PubChem = 2763156 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 2043845 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 172139 | UNII_Ref= {{fdacite|correct|FDA}} | UNII = L0P1807EUY | synonyms = 5-Methoxy-''N''-methyl-''N''-isopropyltryptamine; Moxy; Moxie; MSD-001; MSD001

| IUPAC_name = ''N''-[2-(5-methoxy-1''H''-indol-3-yl)ethyl]-''N''-methylpropan-2-amine | C=15 | H=22 | N=2 | O=1 | SMILES = O(c1cc2c(cc1)[nH]cc2CCN(C(C)C)C)C | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C15H22N2O/c1-11(2)17(3)8-7-12-10-16-15-6-5-13(18-4)9-14(12)15/h5-6,9-11,16H,7-8H2,1-4H3 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = HEDOODBJFVUQMS-UHFFFAOYSA-N

| melting_point = 100 | melting_high = 244 | melting_notes = (free base)<ref name="Erowid-5-MeO-MiPT-Chem" /><ref name="SWGDRUG" /> {{convert|162|to|163|C|F}} (hydrochloride)<ref name="TiHKAL" /> | boiling_point = | boiling_notes = | solubility = }}

'''5-MeO-MiPT''', also known as '''5-methoxy-''N''-methyl-''N''-isopropyltryptamine''' or by its nickname '''Moxy''', is an atypical psychedelic drug of the tryptamine and 5-methoxytryptamine families.<ref name="TiHKAL" /><ref name="Aragon_2024">{{cite web | vauthors = Aragón M | title = Meet Moxy: The Novel Psychedelic the DEA Tried To Ban | date = 9 January 2024 | website = DoubleBlind Mag | url = https://doubleblindmag.com/what-is-moxy/ | access-date = 8 October 2025 }}</ref><ref name="Mullin_2025">{{cite magazine | vauthors = Mullin E | title = A Startup Used AI to Make a Psychedelic Without the Trip | date = 24 September 2025 | magazine = WIRED | url = https://www.wired.com/story/a-startup-used-ai-to-make-a-psychedelic-without-the-trip/ | access-date = 12 November 2025 }}</ref> It has unique and unusual effects compared to other psychedelic tryptamines.<ref name="TiHKAL" /><ref name="Aragon_2024" /><ref name="Palamar_2020" /><ref name="Mullin_2025" /><ref name="Aipsin">{{cite web | title = 5-MeO-MiPT | website = АИПСИН | url = https://aipsin.com/newsubstance/1109/ | language = ru | access-date = 13 November 2025 }}</ref> At low doses, its effects include stimulation, tactile and sexual enhancement, some MDMA-like entactogenic effects, and introspective and mild perceptual changes with few or no psychedelic visuals or time dilation, whereas at higher doses, it produces 5-MeO-DMT-like classical psychedelic effects.<ref name="TiHKAL" /><ref name="Aragon_2024" /><ref name="Palamar_2020" /> It is usually taken orally or smoked.<ref name="TiHKAL" />

The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, among others.<ref name="Rickli_2016">{{cite journal | vauthors = Rickli A, Moning OD, Hoener MC, Liechti ME | title = Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens | journal = European Neuropsychopharmacology | volume = 26 | issue = 8 | pages = 1327–1337 | date = August 2016 | pmid = 27216487 | doi = 10.1016/j.euroneuro.2016.05.001 | s2cid = 6685927 }}</ref><ref name="Puigseslloses_2024">{{cite journal | vauthors = Puigseslloses P, Nadal-Gratacós N, Ketsela G, Weiss N, Berzosa X, Estrada-Tejedor R, Islam MN, Holy M, Niello M, Pubill D, Camarasa J, Escubedo E, Sitte HH, López-Arnau R | title = Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties | journal = Molecular Psychiatry | volume = 29 | issue = 8 | pages = 2346–2358 | date = August 2024 | pmid = 38486047 | pmc = 11412900 | doi = 10.1038/s41380-024-02506-8 }}</ref><ref name="Ray_2010">{{cite journal | vauthors = Ray TS | title = Psychedelics and the human receptorome | journal = PLOS ONE | volume = 5 | issue = 2 | date = February 2010 | pmid = 20126400 | pmc = 2814854 | doi = 10.1371/journal.pone.0009019 | bibcode = 2010PLoSO...5.9019R | doi-access = free | article-number = e9019 }}</ref> It is closely related in chemical structure and effects to 5-MeO-DiPT, and is also related to other tryptamines like 5-MeO-DMT, 4-HO-MiPT, and MiPT.<ref name="TiHKAL" /><ref name="Aragon_2024" /><ref name="Palamar_2020" />

5-MeO-MiPT was first described in the literature by Alexander Shulgin and David Repke and colleagues in 1985.<ref name="Aragon_2024" /><ref name="Aipsin" /><ref name="Repke_1985" /> It was later described by Shulgin in greater detail in his 1997 book ''TiHKAL'' (''Tryptamines I Have Known and Loved'').<ref name="TiHKAL" /> Recreational use of 5-MeO-MiPT is significant but relatively rare.<ref name="Aipsin" /> It is often used as a substitute for 5-MeO-DiPT, which has similar effects but was became a controlled substance in the United States in 2003.<ref name="Aipsin" /> The Drug Enforcement Administration (DEA) proposed banning 5-MeO-MiPT as well in the 2020s, but later withdrew its proposal amid public opposition.<ref name="Aragon_2024" /> 5-MeO-MiPT, under the developmental code name '''MSD-001''', is being developed for the treatment of psychiatric disorders by Mindstate Design Labs and is in phase 1 clinical trials for this purpose as of 2025.<ref name="Mullin_2025" /><ref name="AdisInsight" /><ref name="Bayer_2024" /><ref name="NewsDesk_2024" /><ref name="Meissen_2024" />

==Use and effects== In his book ''TiHKAL'' (''Tryptamines I Have Known and Loved''), Alexander Shulgin lists the dose of 5-MeO-MiPT as 4 to 6{{nbsp}}mg orally and 12 to 20{{nbsp}}mg smoked.<ref name="TiHKAL">{{CiteTiHKAL}} {{cite web | title = 5-MeO-MiPT | url = https://www.erowid.org/library/books_online/tihkal/tihkal40.shtml }}</ref><ref name="Aipsin" /> A wider recreational dose range of 0.5 to 20{{nbsp}}mg or more orally has also been reported however.<ref name="Aragon_2024" /><ref name="Luethi_2018">{{cite journal | vauthors = Luethi D, Liechti ME | title = Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics | journal = The International Journal of Neuropsychopharmacology | volume = 21 | issue = 10 | pages = 926–931 | date = October 2018 | pmid = 29850881 | pmc = 6165951 | doi = 10.1093/ijnp/pyy047 }}</ref><ref name="Malaca_2020" /> Oral doses of 1 to 3{{nbsp}}mg have been described as light, 3 to 8{{nbsp}}mg as common or moderate, and 8 to 12{{nbsp}}mg as strong.<ref name="Malaca_2020" /> Its onset of action when taken orally is described as very rapid, occurring within 15 to 45{{nbsp}}minutes, peak effects appear to occur after around 1 to 2{{nbsp}}hours, and its duration as 4 to 6{{nbsp}}hours.<ref name="TiHKAL" /><ref name="Aipsin" /> However, other sources state its duration as 3 to 8{{nbsp}}hours.<ref name="Aragon_2024" /><ref name="Malaca_2020">{{cite journal | vauthors = Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA | title = Toxicology and Analysis of Psychoactive Tryptamines | journal = International Journal of Molecular Sciences | volume = 21 | issue = 23 | pages = 9279 | date = December 2020 | pmid = 33291798 | pmc = 7730282 | doi = 10.3390/ijms21239279 | quote = 5-Methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT): 5-MeO-MiPT or "moxy" was marketed as a "plant fertilizer". Oral doses ranged from 1–3 mg (light), 3–8 mg (common) and 8–12 mg (strong), with typical 10–20 mg doses if inhaled [22,103]. The principal effects lasted 3–7 h and included a general heightening of awareness, mild euphoria, psychedelic visual effects, such as enhanced colors but also anxiety, nausea, confusion and paranoia. Repke et al. studied if the effects of the drug would differ depending upon the route of administration [104]. If ingested the effects were stimulating, with visual hallucinations prevailing. 5-MeO-MiPT metabolism studied by LC-HRMS/MS identified six phase I metabolites following N-demethylation, O-demethylation, demethylation and hydroxylation and N-oxide formation and hydroxylation of the parent compound and N-O-bis-demethylation of the metabolite 5-OH-MiPT [105]. | doi-access = free }}</ref> A clinical trial confirmed that 5-MeO-MiPT has an onset of about 30{{nbsp}}minutes and that peak effects occur after about 1.5 to 2{{nbsp}}hours.<ref name="Mullin_2025" /> Its duration smoked is said to be 2 to 5{{nbsp}}hours.<ref name="Aipsin" />

5-MeO-MiPT has been described as having unique and unusual effects relative to other psychedelic tryptamines.<ref name="TiHKAL" /><ref name="Aragon_2024" /><ref name="Palamar_2020" /> The effects of 5-MeO-MiPT differ depending on whether it is taken orally or smoked and are highly dose-dependent.<ref name="TiHKAL" /><ref name="Aragon_2024" /> When taken orally at relatively low doses like 4 to 6{{nbsp}}mg, it is usually described as not producing psychedelic visuals or related sensory effects and as producing only hints of time dilation.<ref name="TiHKAL" /><ref name="Aragon_2024" /> However, it is said to produce a stoned state that includes an ease of interpretive fantasy, dream-like perception, intense conceptual thought and philosophical thinking, and mild perceptual effects like altered depth perception, minor wave pattern in peripheral vision, and slightly enhanced auditory acuity.<ref name="TiHKAL" /> Moreover, the drug is described as producing stimulation, greatly enhanced tactile sensation and eroticism, enhanced music appreciation, tingling, shakes, and mild motor impairment.<ref name="TiHKAL" /><ref name="Aragon_2024" /> Its head space is described as relatively "shallow", less confusing, and more easily tolerated compared to classical psychedelics.<ref name="Aragon_2024" /> Its effects have been described by users variably as both pleasant and negative.<ref name="TiHKAL" /><ref name="Aragon_2024" />

When smoked, 5-MeO-MiPT is described as having effects similar in many regards to those of 5-MeO-DMT.<ref name="TiHKAL" /> These effects of smoked 5-MeO-MiPT include a powerful rush (but less intense than 5-MeO-DMT), loss of coherent thought, not much in the way of visuals, closed-eye visuals of moving and colored geometric patterns, intense waves of mental imagery of emotionally infused memories, impressive recall of early memories, intense depersonalization or disorientation of the normal sense of being a person in a body, loss of immediate contact with surroundings, emotional lability including laughing, crying, and vocal outbursts, groaning, writhing, shaking around, and general disorientation.<ref name="TiHKAL" /> It is described as having a very rapid onset, with the peak phase lasting less than 30{{nbsp}}minutes and waves continuing for up to a few hours.<ref name="TiHKAL" /> It was described by one user as feeling like a hybrid between diethyltryptamine (DET) and 5-MeO-DMT.<ref name="TiHKAL" />

5-MeO-MiPT is also known by its nickname "Moxy"<ref name="Aragon_2024" /> and is closely related both in terms of chemical structure and effects to 5-MeO-DiPT (also known as "Foxy Methoxy").<ref name="TiHKAL" /><ref name="Palamar_2020">{{cite journal | vauthors = Palamar JJ, Acosta P | title = A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines | journal = Human Psychopharmacology | volume = 35 | issue = 1 | date = January 2020 | pmid = 31909513 | pmc = 6995261 | doi = 10.1002/hup.2719 | quote = 5-Meo-DIPT, Foxy, or Moxy (5-Meo-MIPT) are tryptamines that are distinct. A lot of people I know that like them think they're very aphrodisiac and much more stimulant and a party drug. My opinion on 5-MeO-MIPT is that it was a very sexual chemical ... it feels good to touch things, and that sort of sensation certainly lends itself to sex but I wouldn't call it innately an aphrodisiac. | article-number = e2719 }}</ref> These two serotonergic tryptamines at low doses have been described as very aphrodisiac and much more stimulant-like and party drugs than classical psychedelics.<ref name="Palamar_2020" /> However, they have been described as not innately aphrodisiac, but instead as enhancing tactile sensation in a way that lends itself to sex.<ref name="Palamar_2020" /> Matthew Baggott has described 5-MeO-MiPT as having some MDMA-like entactogenic effects at low doses, including tactile enhancement and feelings of empathy, intimacy, and closeness with others, and as producing classical psychedelic effects at higher doses.<ref name="Carpenter_2022">{{Cite web | vauthors = Carpenter DE | title = DEA Proposes Adding Five Psychedelic Compounds to Schedule 1 | date = 2022-01-25 | url = https://www.lucid.news/dea-proposes-five-psychedelic-compounds-schedule-1/ | access-date = 2022-01-26 | website = Lucid News | language = en-US }}</ref>

Mindstate Design Labs has described 5-MeO-MiPT as the "least psychedelic psychedelic that's psychoactive".<ref name="Mullin_2025" /> It is described as being quite psychoactive, but as lacking "hallucinations" and as not producing "mind-bending trips".<ref name="Mullin_2025" /><ref name="Krol2026" /> The drug was assessed at five different doses (up to at least 10{{nbsp}}mg) by oral administration in a phase 1 clinical trial in 47{{nbsp}}individuals.<ref name="Mullin_2025" /><ref name="Krol2026">{{cite conference | vauthors = Krol F | title = Safety, pharmacokinetics, and pharmacodynamics of MSD-001 after single dosing in healthy adults: a randomized, double-blind, placebo-controlled study | date = 2026 | conference = Interdisciplinary Conference on Psychedelic Research (ICPR) 2026 | publisher = OPEN Foundation | url = https://www.icpr-conference.com/poster-presentations#:~:text=Safety%2C%20pharmacokinetics%2C%20and,Fas%20Krol | quote=Background: MSD-001 (5-MeO-MiPT) is an orally bioavailable tryptamine targeting 5-HT1A, 5-HT7, and 5-HT1D receptors, selected to produce mild psychoactive effects. This first-in-human study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses (0.5-10 mg) in healthy volunteers. Methods: In this randomized, double-blind, placebo-controlled study, participants received single doses of MSD-001 or placebo. Subjects were stratified by CYP2D6 status: intermediate/extensive metabolizers (IM/EM) received 0.5-10 mg, and poor metabolizers (PM) received 0.5-3 mg. Safety assessments included AEs, ECGs, labs, and psychiatric evaluations. PK was assessed noncompartmentally. PD measures included subjective scales (RTI, 5D-ASC, VAS), EEG, fMRI, and NeuroCart testing. Results: 47 participants were enrolled (40 IM/EM, 7 PM). MSD-001 was safe and well tolerated, with no serious AEs. Most AEs were mild and dose-related, commonly including visual effects, euphoria, and relaxation. No clinically meaningful cardiovascular or psychiatric effects were observed. MSD-001 was rapidly absorbed (Tmax 1-2 h; t½ ~2-3 h). Exposure increased with dose, plateauing at 6-10 mg. PMs showed ~1.6-1.8× higher exposure and longer half-life than IM/EMs. Dose-dependent PD effects were observed, minimal at 0.5-1 mg and most consistent at 6-10 mg. Effects began within 30 minutes, peaked at 2-3 hours, and resolved by 6 hours. Subjective effects included visual and mood changes without anxiety. EEG showed reduced delta/theta and increased gamma activity, while fMRI and NeuroCart effects were limited. Conclusions: Single doses of MSD-001 up to 10 mg were safe and well tolerated, with predictable PK and dose-related effects influenced by CYP2D6 status.}}</ref><ref name="NCT06702332">{{cite web | title=Single Ascending Dose Study of MSD-001 in Healthy Participants | website=ClinicalTrials.gov | url=https://clinicaltrials.gov/study/NCT06702332 | access-date=8 February 2026}}</ref><ref name="CTIS2025">{{cite web | title=Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants | website=CTIS.eu Clinical Trials | date=10 May 2025 | url=https://ctis.eu/search/trial/2024-512939-67-00.html}}</ref> Its effects were minimal at 0.5 to 1{{nbsp}}mg orally and were most consistent at doses of 6 to 10{{nbsp}}mg orally.<ref name="Krol2026" /> The effects included heightened emotions, euphoria and relaxation, associative thinking, enhanced imagination, and perceptual or visual effects such as brighter colors.<ref name="Mullin_2025" /><ref name="Krol2026" /> However, there were no "hallucinations", self-disintegration, oceanic boundlessness, or other typical features of psychedelic experiences.<ref name="Mullin_2025" /><ref name="Krol2026" /> Its onset was 30{{nbsp}}minutes, its peak of effects was 1.5 to 3{{nbsp}}hours, and its duration was 6{{nbsp}}hours.<ref name="Mullin_2025" /><ref name="Krol2026" /> Mindstate Design Labs has hypothesized that a mild psychedelic experience, as with 5-MeO-MiPT, could still provide therapeutic benefits without overt hallucinogenic effects.<ref name="Mullin_2025" /><ref name="Krol2026" />

In addition to its use on its own, 5-MeO-MiPT, along with the related tryptamine psychedelic 4-HO-MET, is employed as a component of the MDMA-mimicking Borax combo.<ref name="Aragon_2024" /><ref name="Baggott_2023">{{cite conference | vauthors = Baggott M | title = Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine | location = Denver, CO | date = 23 June 2023 | conference = PS2023 [Psychedelic Science 2023, June 19–23, 2023, Denver, Colorado] | publisher = Multidisciplinary Association for Psychedelic Studies | url = https://2023.psychedelicscience.org/sessions/beyond-ecstasy-progress-in-developing-and-understanding-a-novel-class-of-therapeutic-medicine/ }}</ref><ref name="MorrisBaggott2023">{{cite podcast | title = POD 92: Understanding and Improving MDMA with Dr. Matthew Baggott | date = 28 November 2023 | url = https://www.patreon.com/posts/pod-92-and-mdma-93714355 | website = The Hamilton Morris Podcast | publisher = Patreon | host = Hamilton Morris | access-date = 30 November 2024 }}</ref><ref name="NADDI2022">{{cite web | title = Borax Combo (Synonyms: Blue Bliss) | date = 14 December 2022 | website = naddi.org | publisher = National Association of Drug Diversion Investigators (NADDI) | url = https://www.naddi.org/glossary/borax-combo/ | access-date = 21 November 2024 }}</ref>

==Side effects== Adverse effects of 5-MeO-MiPT include loss of appetite and insomnia.<ref name="TiHKAL" /> It produced no meaningful cardiovascular or psychiatric adverse effects in a phase 1 clinical trial, including no anxiety.<ref name="Krol2026" /> Low-dose 5-MeO-MiPT did not cause any serious histopathological effects on the liver, kidney, and brain. High doses induce apoptotic cell death through caspase activity especially in some parts of the organs.<ref name="Altunc_2021">{{cite journal | vauthors = Altuncı YA, Aydoğdu M, Açıkgöz E, Güven Ü, Düzağaç F, Atasoy A, Dağlıoğlu N, Annette Akgür S | title = New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study | journal = Balkan Medical Journal | volume = 38 | issue = 1 | pages = 34–42 | date = January 2021 | pmid = 32936075 | pmc = 8909217 | doi = 10.4274/balkanmedj.galenos.2020.2019.11.68 }}</ref> There is no known documentation of death attributed to the use of 5-MeO-MiPT alone.<ref name="Aragon_2024" />

==Interactions== {{See also|Psychedelic drug#Interactions|Trip killer#Serotonergic psychedelic antidotes}}

==Pharmacology== ===Pharmacodynamics=== {| class="wikitable floatright" style="font-size:small;" |+ 5-MeO-MiPT activities |- ! Target !! Affinity (Ki, nM) |- | 5-HT1A || 12–143 (Ki) 37–>10,000 ({{Abbrlink|EC50|Half-maximal effective concentration}}) 108–109% ({{Abbrlink|Emax|maximal efficacy}}) |- | 5-HT1B || 303–728 |- | 5-HT1D || 23–103 |- | 5-HT1E || 3,496–>10,000 |- | 5-HT1F || {{Abbr|ND|No data}} |- | 5-HT2A || 113–449 (Ki) 5.9–566 ({{Abbr|EC50|Half-maximal effective concentration}}) 82–107% ({{Abbr|Emax|maximal efficacy}}) |- | 5-HT2B || 53–59 (Ki) 44–1,500 ({{Abbr|EC50|Half-maximal effective concentration}}) 12–88% ({{Abbr|Emax|maximal efficacy}}) |- | 5-HT2C || 790–2,186 (Ki) 39–745 ({{Abbr|EC50|Half-maximal effective concentration}}) 90–115% ({{Abbr|Emax|maximal efficacy}}) |- | 5-HT3 || >10,000 |- | 5-HT4 || {{Abbr|ND|No data}} |- | 5-HT5A || 953–>10,000 |- | 5-HT6 || 130–281 |- | 5-HT7 || 20–122 |- | α1A || >12,000 |- | α1B || >10,000 |- | α2A || 175–>10,000 |- | α2B || 1,693–>10,000 |- | α2C || 637–2174 |- | β1–β2 || >10,000 |- | D1 || >25,000 |- | D2 || >25,000 |- | D3 || 2,470–>25,000 |- | D4 || 1,422–6,331 |- | D5 || >10,000 |- | H1 || 3,900–>10,000 |- | H2–H4 || >10,000 |- | I1 || 879 |- | TAAR1 || >15,000 (rat/mouse) |- | σ1 || 1,666–>10,000 |- | σ2 || 90–918 |- | {{Abbrlink|SERT|Serotonin transporter}} || 3,300–>10,000 (Ki) 2,680–29,768 ({{Abbrlink|IC50|half-maximal inhibitory concentration}}) >100,000 ({{Abbr|EC50|half-maximal effective concentration}}) |- | {{Abbrlink|NET|Norepinephrine transporter}} || >22,000 (Ki) 84,000 ({{Abbr|IC50|half-maximal inhibitory concentration}}) >100,000 ({{Abbr|EC50|half-maximal effective concentration}}) |- | {{Abbrlink|DAT|Dopamine transporter}} || >26,000 (Ki) >100,000 ({{Abbr|IC50|half-maximal inhibitory concentration}}) >100,000 ({{Abbr|EC50|half-maximal effective concentration}}) |- class="sortbottom" | colspan="2" style="width: 1px; background-color:var(--background-color-notice-subtle,#eaecf0); color:inherit; text-align: center;" | '''Notes:''' The smaller the value, the more avidly the drug interacts with the site. '''Refs:''' <ref name="Rickli_2016" /><ref name="Puigseslloses_2024" /><ref name="Ray_2010" /><ref name="Nagai_2007" /><ref name="Blough_2014">{{cite journal | vauthors = Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB | title = Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes | journal = Psychopharmacology | volume = 231 | issue = 21 | pages = 4135–4144 | date = October 2014 | pmid = 24800892 | pmc = 4194234 | doi = 10.1007/s00213-014-3557-7 }}</ref><ref name="Kozell_2023">{{cite journal | vauthors = Kozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, Schmachtenberg JL, Olson RJ, Janowsky A, Abbas AI | title = Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 385 | issue = 1 | pages = 62–75 | date = April 2023 | pmid = 36669875 | pmc = 10029822 | doi = 10.1124/jpet.122.001454 }}</ref><ref name="Glatfelter_2024">{{cite journal | vauthors = Glatfelter GC, Clark AA, Cavalco NG, Landavazo A, Partilla JS, Naeem M, Golen JA, Chadeayne AR, Manke DR, Blough BE, McCorvy JD, Baumann MH | title = Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-''N'',''N''-dimethyltryptamine Analogs in Mice | journal = ACS Chemical Neuroscience | volume = 15 | issue = 24 | pages = 4458–4477 | date = December 2024 | pmid = 39636099 | doi = 10.1021/acschemneuro.4c00513 | pmc = 12745965 }}</ref> |}

The mechanism that produces the hallucinogenic effects of 5-MeO-MiPT is thought to result primarily from serotonin 5-HT2A receptor agonism combined with the 5-HT1A receptor activation.<ref name="Repke_1985">{{cite journal | vauthors = Repke DB, Grotjahn DB, Shulgin AT | title = Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents | journal = Journal of Medicinal Chemistry | volume = 28 | issue = 7 | pages = 892–896 | date = July 1985 | pmid = 4009612 | doi = 10.1021/jm00145a007 }}</ref><ref name="Nagai_2007">{{cite journal | vauthors = Nagai F, Nonaka R, Satoh Hisashi Kamimura K | title = The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | journal = European Journal of Pharmacology | volume = 559 | issue = 2–3 | pages = 132–137 | date = March 2007 | pmid = 17223101 | doi = 10.1016/j.ejphar.2006.11.075 }}</ref> 5-MeO-MiPT also potently binds to 5-HT2B receptor with high affinity but low efficacy, 5-HT2C receptors with moderate potency, and displays sub-micromolar affinity towards multiple other serotonin receptors.<ref name="Rickli_2016" /><ref name="Glatfelter_2024" />

The drug generally displays higher binding affinity for the 5-HT1A over 5-HT2A receptor.<ref name="Rickli_2016" /><ref name="Puigseslloses_2024" /> It was also included in the group of 5-methoxytryptamines for which computational docking analyses predicted a more favorable interaction in the 5-HT1A binding pocket compared to 5-HT2A receptor.<ref name="Puigseslloses_2024" /> In contrast, assays yielded a wide range of results, with some showing comparable and one no activity up to 10 μM concentrations.<ref name="Blough_2014" /> A 2024 BRET ''in vitro'' functional assay measuring G protein dissociation in humans found the drug to be one the few 5-HT2A-preferring 5-methoxytryptamines with a roughly 2-fold higher potency.<ref name="Glatfelter_2024" /> In mice, 5‑MeO‑MiPT produces hypothermia at high doses (30 mg/kg.)<ref name="Bassi_2024" />

In addition to the serotonin receptors, 5-MeO-MiPT has also been found to show significant affinity to the serotonin transporter (SERT) and norepinephrine transporter (NET), thereby acting as a moderately potent serotonin–norepinephrine reuptake inhibitor (SNRI).<ref name="Ray_2010" /><ref name="Nagai_2007" /> However, subsequent research contradicted the preceding findings and found that 5-MeO-MiPT did not significantly bind to or inhibit the human monoamine transporters.<ref name="Rickli_2016" /><ref name="Puigseslloses_2024" /><ref name="Blough_2014" /><ref name="Glatfelter_2024" /> The drug is also inactive as a monoamine releasing agent.<ref name="Puigseslloses_2024" /><ref name="Nagai_2007" />

Aside from those targets 5-MeO-MiPT was found to bind with sub-micromolar affinity to σ2, α2-adrenergic, and imidazoline-1 receptors.<ref name="Rickli_2016" /><ref name="Glatfelter_2024" />

====Neurotoxicity==== {{See also|Psychedelic drug#Neurotoxicity}}

5-MeO-MiPT has been found to produce neurotoxicity at high (2.7 mg/kg) but not low (0.27{{nbsp}}mg/kg) doses in mice.<ref name="RudinLiechtiLuethi2021">{{cite journal | vauthors = Rudin D, Liechti ME, Luethi D | title = Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics | journal = Exp Neurol | volume = 343 | issue = | article-number = 113778 | date = September 2021 | pmid = 34090893 | doi = 10.1016/j.expneurol.2021.113778 | url = | quote = The tryptamine NPS 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT) has been shown to induce apoptotic cell death through caspase activity in mouse brain at high doses (2.7 mg/kg) (Altuncı et al., 2021).| doi-access = free }}</ref><ref name="AltuncıAydoğduAçıkgöz2021">{{cite journal | vauthors = Altuncı YA, Aydoğdu M, Açıkgöz E, Güven Ü, Düzağaç F, Atasoy A, Dağlıoğlu N, Annette Akgür S | title = New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study | journal = Balkan Med J | volume = 38 | issue = 1 | pages = 34–42 | date = January 2021 | pmid = 32936075 | pmc = 8909217 | doi = 10.4274/balkanmedj.galenos.2020.2019.11.68 | url = }}</ref> The drug itself does not appear to have been studied, but the closely related drug 5-MeO-DiPT has been found to produce serotonergic neurotoxicity, genotoxicity, and associated cognitive deficits in rodents.<ref name="Araujo_2015">{{cite journal | vauthors = Araújo AM, Carvalho F, Bastos M, Guedes de Pinho P, Carvalho M | title = The hallucinogenic world of tryptamines: an updated review | journal = Archives of Toxicology | volume = 89 | issue = 8 | pages = 1151–1173 | date = August 2015 | pmid = 25877327 | doi = 10.1007/s00204-015-1513-x | bibcode = 2015ArTox..89.1151A }}</ref><ref name="Compton_2011">{{cite journal | vauthors = Compton DM, Dietrich KL, Selinger MC, Testa EK | title = 5-methoxy-N,N-di(iso)propyltryptamine hydrochloride (Foxy)-induced cognitive deficits in rat after exposure in adolescence | journal = Physiology & Behavior | volume = 103 | issue = 2 | pages = 203–209 | date = May 2011 | pmid = 21295050 | doi = 10.1016/j.physbeh.2011.01.021 }}</ref><ref name="Skelton_2009">{{cite journal | vauthors = Skelton MR, Schaefer TL, Herring NR, Grace CE, Vorhees CV, Williams MT | title = Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats | journal = Psychopharmacology | volume = 204 | issue = 2 | pages = 287–297 | date = June 2009 | pmid = 19198809 | pmc = 2888297 | doi = 10.1007/s00213-009-1459-x }}</ref><ref name="NoworytaSokoowska_2016">{{cite journal | vauthors = Noworyta-Sokołowska K, Kamińska K, Kreiner G, Rogóż Z, Gołembiowska K | title = Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats | journal = Neurotoxicity Research | volume = 30 | issue = 4 | pages = 606–619 | date = November 2016 | pmid = 27461536 | pmc = 5047954 | doi = 10.1007/s12640-016-9654-0 }}</ref><ref name="NoworytaSokoowska_2019">{{cite journal | vauthors = Noworyta-Sokołowska K, Kamińska K, Rzemieniec J, Wnuk A, Wojcieszak J, Górska AM, Kreiner G, Kajta M, Gołembiowska K | title = Effects of exposure to 5-MeO-DIPT during adolescence on brain neurotransmission and neurotoxicity in adult rats | journal = Forensic Toxicology | volume = 37 | issue = 1 | pages = 45–58 | date = 2019 | pmid = 30636982 | pmc = 6315008 | doi = 10.1007/s11419-018-0433-x }}</ref> Other psychedelics have also been found to produce neurotoxicity in preclinical research.<ref name="RudinLiechtiLuethi2021" /><ref name="CustodioOrtizLee2025">{{cite journal | vauthors = Custodio RJ, Ortiz DM, Lee HJ, Sayson LV, Kim M, Lee YS, Kim KM, Cheong JH, Kim HJ | title = Serotonin 2C receptors are also important in head-twitch responses in male mice | journal = Psychopharmacology (Berl) | volume = 242 | issue = 7 | pages = 1585–1605 | date = July 2025 | pmid = 37882810 | doi = 10.1007/s00213-023-06482-9 | url = }}</ref><ref name="CapelaRuscherLautenschlager2006">{{cite journal | vauthors = Capela JP, Ruscher K, Lautenschlager M, Freyer D, Dirnagl U, Gaio AR, Bastos ML, Meisel A, Carvalho F | title = Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia | journal = Neuroscience | volume = 139 | issue = 3 | pages = 1069–1081 | date = 2006 | pmid = 16504407 | doi = 10.1016/j.neuroscience.2006.01.007 | url = }}</ref><ref name="CapelaCarmoRemião2009">{{cite journal | vauthors = Capela JP, Carmo H, Remião F, Bastos ML, Meisel A, Carvalho F | title = Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview | journal = Mol Neurobiol | volume = 39 | issue = 3 | pages = 210–271 | date = June 2009 | pmid = 19373443 | doi = 10.1007/s12035-009-8064-1 | url = | quote = To further corroborate the fact that MDMA agonistic properties at the 5-HT2A receptor could produce neuronal death, DOI, a prototypical agonist of that receptor was added to cortical neurons [289]. DOI (10 to 100 μM for 24 or 48 h) also induced a dose- and time-dependent apoptotic cortical neuronal apoptosis, which was attenuated by ketanserin and R-96544 [289]. Ketanserin and R-96544 are competitive selective 5-HT2A receptor antagonists and only attenuated MDMA-induced cortical neurodegeneration. However, an antibody raised against the 5-HT2A-receptor, an "irreversible" non-competitive 5-HT2A receptor blocker, prevented almost completely MDMA- and DOI-induced cortical neurotoxicity [289, 290]. Neuronal apoptosis mediated by MDMA is accompanied by activation of caspase 3, which could be blocked by the antibody raised against the 5-HT2A receptor [290]. Therefore, it is likely that DOI- and MDMA-induced neuronal apoptosis arises from direct stimulation of the 5-HT2A receptor [289, 290].}}</ref>

===Pharmacokinetics=== ====Absorption==== Following intraperitoneal administration of 5-MeO-MiPT at doses of 2.7{{nbsp}}mg/kg in mice the compound was detectable in blood, kidney, liver, and brain.<ref name="Altunc_2021" /> At lower doses of 0.27{{nbsp}}mg/kg, concentrations of the parent compound remained below the limit of quantification in all samples.<ref name="Altunc_2021" />

In one human case report 5-MeO-MiPT concentrations were measured at 160{{nbsp}}ng/mL in blood and 3,380{{nbsp}}ng/mL in urine samples collected approximately one and two hours post-exposure, respectively.<ref name="Grafinger_2018">{{cite journal | vauthors = Grafinger KE, Hädener M, König S, Weinmann W | title = Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples | journal = Drug Testing and Analysis | volume = 10 | issue = 3 | pages = 562–574 | date = March 2018 | pmid = 28677880 | doi = 10.1002/dta.2245 }}</ref>

The time to peak levels of 5-MeO-MiPT taken orally in humans is 1 to 2{{nbsp}}hours.<ref name="Krol2026" />

====Distribution==== ''In silico'' ADMET predictions projected high jejunal permeability and very high kidney permeability in MDCK cells, which suggests efficient gastrointestinal absorption and renal filtration.<ref name="Bassi_2024">{{cite journal | vauthors = Bassi M, Bilel S, Tirri M, Corli G, Di Rosa F, Gregori A, Alkilany AM, Rachid O, Roda E, Zauli G, Locatelli CA, Marti M | title = Pharmaco-toxicological effects of the novel tryptamine hallucinogen 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters in mice-from a human poisoning case to the preclinical evidence | journal = Psychopharmacology | volume = 241 | issue = 3 | pages = 489–511 | date = March 2024 | pmid = 38214743 | pmc = 10884077 | doi = 10.1007/s00213-024-06526-8 }}</ref> The compound demonstrated nearly complete blood-brain barrier penetration (99% predicted), and was not predicted to be a substrate for P-glycoprotein, or organic anion transporters.<ref name="Bassi_2024" /> The predicted human percent unbound to blood plasma proteins was 45.5%, compared to 31.6% in mice.<ref name="Bassi_2024" /> The predicted volume of distribution (Vd) for 5-MeO-MiPT was 3.743{{nbsp}}L/kg, lower than its structural analogue 5-MeO-DiPT (4.219{{nbsp}}L/kg) and DMT (4.396{{nbsp}}L/kg).<ref name="Bassi_2024" />

====Metabolism==== 5-MeO-MiPT undergoes extensive phase I hepatic metabolism, mediated by cytochrome P450 enzymes. ''In vitro'' experiments using pooled human liver microsomes identified seven phase I metabolites, of which five were found ''in vivo''.<ref name="Grafinger_2018" /><ref name="Wang_2024">{{cite journal | vauthors = Wang Y, Zhong C, Chen J, Meng L | title = Biotransformation of 5-methoxy-N-isopropyl-N-methyltryptamine by zebrafish and human liver microsome with high-resolution mass spectrometry | journal = Journal of Pharmaceutical and Biomedical Analysis | volume = 241 | article-number = 115987 | date = April 2024 | pmid = 38280235 | doi = 10.1016/j.jpba.2024.115987 }}</ref> The major metabolic pathways include ''O''-demethylation, ''N''-demethylation, hydroxylation, and ''N''-oxide formation.<ref name="Grafinger_2018" /><ref name="Wang_2024" /> The metabolic profile of 5-MeO-MiPT shows similarity to the structurally related compound 5-MeO-DiPT.<ref name="Grafinger_2018" /> 5-MeO-MiPT is metabolized by CYP2D6 in humans, with CYP2D6 poor metabolizers showing 1.6- to 1.8-fold higher exposure and longer elimination half-life than extensive metabolizers.<ref name="Krol2026" />

''In vivo'' analysis of forensic case sample identified five phase I metabolites in blood and seven in urine. The metabolites detected in both blood and urine included 5-MeO-NiPT, 5-HO-MiPT, 5-MeO-MiPT-''N''-oxide, and HO-5-MeO-MiPT.<ref name="Grafinger_2018" /> Two additional phase II metabolites (glucuronides) were found in mice and ''in vitro'' models, but not in human urine sample.<ref name="Grafinger_2018" /><ref name="Wang_2024" /><ref>{{cite journal | vauthors = Fabregat-Safont D, Barneo-Muñoz M, Martinez-Garcia F, Sancho JV, Hernández F, Ibáñez M | title = Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice | journal = Journal of Chromatography A | volume = 1508 | pages = 95–105 | date = July 2017 | pmid = 28602505 | doi = 10.1016/j.chroma.2017.06.010 }}</ref>

In silico ADMET predicted the compound to be a substrate but not an inhibitor for the CYP1A2 and CYP2C9 enzymes, and a substrate for CYP2A6 and CYP2B6.<ref name="Bassi_2024" /> Additionally, the compound is predicted to be both a substrate and inhibitor for the CYP2D6 enzyme.<ref name="Bassi_2024" />

Detection of multiple metabolites in human urine sample two hours post-exposure, along with measurable blood concentrations at one hour, suggest relatively rapid metabolism and elimination.<ref name="Grafinger_2018" /> Renal excretion is likely a major route of elimination.<ref name="Grafinger_2018" />

====Elimination==== The elimination half-life of 5-MeO-MiPT is approximately 2 to 3{{nbsp}}hours.<ref name="Krol2026" />

==Chemistry== 5-MeO-MiPT, also known as 5-methoxy-''N''-methyl-''N''-isopropyltryptamine, is a substituted tryptamine, 5-methoxytryptamine, and ''N'',''N''-dialkyltryptamine.<ref name="TiHKAL" /> It is the ''N''-methyl-''N''-isopropyl homologue of 5-MeO-DMT (5-methoxy-''N'',''N''-dimethyltryptamine).<ref name="TiHKAL" />

===Properties=== 5-MeO-MiPT free base is a solid and is said to be a white or yellow crystalline powder<ref name="SWGDRUG">https://www.swgdrug.org/Monographs/5-MeO-MiPT.pdf</ref><ref name="DHHS2012">https://web.archive.org/web/20250526074239/https://downloads.regulations.gov/DEA-2022-0001-0007/content.pdf</ref> or to be light to dark orange in color.<ref name="ChemicalBook">{{cite web | title=96096-55-8 CAS MSDS (5-MEO-MIPT) Melting Point Boiling Point Density CAS Chemical Properties | website=ChemicalBook | url=https://www.chemicalbook.com/ChemicalProductProperty_US_CB4104540.aspx | access-date=2026-03-05}}</ref> It has a bitter taste.<ref name="Erowid-5-MeO-MiPT-Chem" /> The molecular weight of the free base is 246.35{{nbsp}}g/mol,<ref name="PubChem">{{cite web | title=5-methoxy-N-methyl-N-(1-methylethyl)-1H-Indole-3-ethanamine | website=PubChem | url=https://pubchem.ncbi.nlm.nih.gov/compound/2763156 | access-date=5 March 2026}}</ref> while the molecular weight of the hydrochloride salt is 282.81{{nbsp}}g/mol.<ref name="PubChem-HCl">{{cite web | title=5-Methoxy-N-methyl-N-isopropyltryptamine hydrochloride | website=PubChem | url=https://pubchem.ncbi.nlm.nih.gov/compound/24802247 | access-date=5 March 2026}}</ref>

The melting point of 5-MeO-MiPT free base is said to be between 100 and 150 °C<ref name="Erowid-5-MeO-MiPT-Chem">{{cite web | title=Erowid 5-MeO-MIPT Vault : Chemistry | website=Erowid | date=2015-02-21 | url=https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt_chemistry.shtml | access-date=2026-03-05}}</ref> or to be 243.7 °C,<ref name="SWGDRUG" /> while the melting point of 5-MeO-MiPT hydrochloride is 162 to 163 °C.<ref name="TiHKAL" />

5-MeO-MiPT free base is soluble in dimethylformamide (DMF) (30{{nbsp}}mg/mL), dimethyl sulfoxide (DMSO) (30{{nbsp}}mg/mL), and ethanol (30{{nbsp}}mg/mL).<ref name="Cayman2025">https://cdn.caymanchem.com/cdn/msds/11482m.pdf</ref> 5-MeO-MiPT free base dissolves in organic solvents like chloroform, ether, benzene, and acetone but not in water, while 5-MeO-MiPT salts like 5-MeO-MiPT hydrochloride and 5-MeO-MiPT sulfate dissolve in water but not in organic solvents.<ref name="Erowid-5-MeO-MiPT-Chem" />

The chemical stability of 5-MeO-MiPT as a crystalline solid at –20 °C is reported to be at least 5{{nbsp}}years.<ref name="Cayman2023">https://cdn.caymanchem.com/cdn/insert/11482.pdf</ref>

===Synthesis=== The chemical synthesis of 5-MeO-MiPT has been described.<ref name="TiHKAL" />

===Analogues=== Analogues of 5-MeO-MiPT include methylisopropyltryptamine (MiPT), 4-HO-MiPT (miprocin), 4-AcO-MiPT (mipracetin), NB-5-MeO-MiPT, 5-MeO-DMT, 5-MeO-DiPT, 5-MeO-DALT, 5-MeO-MET, 5-MeO-MPT, 5-MeO-MsBT, 5-MeO-EiPT, 5-MeO-PiPT, and 5-MeO-iPALT (ASR-3001), among others.<ref name="TiHKAL" />

====Positional isomers==== 6-MeO-MiPT and 7-MeO-MiPT are positional isomers of 5-MeO-MiPT.<ref name="Shulgin_2003">{{cite book | vauthors = Shulgin AT | veditors = Laing RR | chapter = Basic Pharmacology and Effects | title = Hallucinogens: A Forensic Drug Handbook | pages = 67–137 | year = 2003 | publisher = Elsevier Science | series = Forensic Drug Handbook Series | isbn = 978-0-12-433951-4 | url = https://books.google.com/books?id=l1DrqgobbcwC | chapter-url = https://bibliography.maps.org/resources/download/12634 | archive-url = https://web.archive.org/web/20250713013624/https://bibliography.maps.org/resources/download/12634 | archive-date = 13 July 2025 }}</ref> They have been described by Alexander Shulgin as being inactive at doses of up to 50{{nbsp}}mg and 70{{nbsp}}mg orally, respectively.<ref name="Shulgin_2003" /> Another notable positional isomer is 4-MeO-MiPT.<ref name="TiHKAL" /><ref name="Shulgin_2003" />

=== Detection === 5-MeO-MiPT causes the ehrlich reagent to turn purple then fade to faint blue. It causes the marquis reagent to go yellow through to black.<ref name="Spratley_2004">{{cite journal | vauthors = Spratley T | title = Analytical Profiles for Five "Designer" Tryptamines | journal = Microgram Journal | volume = 3 | issue = 1–2 | pages = 55 | date = 2004 | url = http://www.erowid.org/library/periodicals/microgram/microgram_journal_2005-1.pdf#page=54 | format = PDF | access-date = 2013-10-09 }}</ref>

==History== 5-MeO-MiPT was first described in the scientific literature by Alexander Shulgin and David Repke and colleagues in 1985.<ref name="Aragon_2024" /><ref name="Aipsin" /><ref name="Repke_1985" /> It was later described by Shulgin in greater detail in his 1997 book ''TiHKAL'' (''Tryptamines I Have Known and Loved'').<ref name="TiHKAL" /> The United States Drug Enforcement Administration (DEA) proposed banning 5-MeO-MiPT in the 2020s, but this proposal was later withdrawn.<ref name="Aragon_2024" /> The effort to make 5-MeO-MiPT a controlled substance was prominently opposed by the psychedelic community.<ref name="Aragon_2024" />

==Society and culture== ===Legal status=== thumb|180px|right|Two tablets of 5-MeO-MiPT.

====Canada==== 5-MeO-MiPT is not an explicitly nor implicitly controlled substance in Canada as of 2025.<ref name="CDSA">{{cite web | title = Controlled Drugs and Substances Act | url = https://laws-lois.justice.gc.ca/eng/acts/c-38.8/fulltext.html | website = Justice Laws Website | publisher = Government of Canada | access-date = March 28, 2025 }}</ref>

====China==== As of September–October 2015, China lists 5-MeO-MiPT as a controlled substance.<ref>{{cite web | title = 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | date = 27 September 2015 | url = http://www.sfda.gov.cn/WS01/CL0056/130753.html | trans-title = Notice on Printing and Distributing the "Measures for the Scheduling of Non-Pharmaceutical Narcotic Drugs and Psychotropic Substances" | publisher = China Food and Drug Administration | language = zh | access-date = 1 October 2015 | archive-url = https://web.archive.org/web/20151001222554/http://www.sfda.gov.cn/WS01/CL0056/130753.html | archive-date = 1 October 2015 }}</ref>

====Europe==== Finland includes it in its decree banning certain psychoactive substances from the consumer market.<ref>{{Cite web | title = FINLEX - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta... 1130/2014 | url = https://www.finlex.fi/fi/lainsaadanto/saadoskokoelma/2014/1130 | website = www.finlex.fi | access-date = 11 July 2023 }}</ref> In Luxembourg it is not listed among prohibited substances, making it not illegal but a legal gray area there.<ref>{{cite web | title = Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie | url = http://legilux.public.lu/eli/etat/leg/loi/1973/02/19/n1/jo | trans-title = Law of February 19, 1973 concerning the sale of medicinal substances and the fight against drug addiction | language = fr | work = Journal officiel du Grand-Duché de Luxembourg | trans-work = Official Journal of the Grand Duchy of Luxembourg }}</ref>

====United Kingdom==== In the United Kingdom, it is classified as a Class A drug along with most ethers of ring-hydroxy tryptamines.{{citation needed|date=January 2019}}

====United States==== {{See also|Drug Enforcement Administration#Scheduling of psychedelic drugs}}

In the United States, it is unscheduled at the federal level,<ref>{{Cite web | title = 21 CFR — Schedules of Controlled Substances §1308.11 Schedule I. | url = http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm | access-date = 2014-12-17 | archive-date = 2009-08-27 | archive-url = https://web.archive.org/web/20090827043725/http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm }}</ref> but may be treated as an analogue of 5-MeO-DiPT under the Federal Analog Act therefore if it is sold for human consumption and not for medical or scientific uses is illegal and prosecuted.

At the state level, "5-Methoxy-N-methyl-N-isopropyltryptamine" is classified as a Schedule I controlled substance in Florida, prohibiting its purchase, consumption, sale, or possession.<ref name="Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL">{{cite web | title = Chapter 893 - Drug Abuse Prevention and Control | url = http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html | work = Florida Statutes }}</ref>

==Research== 5-MeO-MiPT, under the developmental code name MSD-001, is being developed for the treatment of psychiatric disorders.<ref name="Mullin_2025" /><ref name="AdisInsight">{{cite web | title = MSD 001 | date = 17 October 2025 | website = AdisInsight | url = https://adisinsight.springer.com/drugs/800080520 | access-date = 12 November 2025 }}</ref><ref name="Bayer_2024">{{cite web | vauthors = Bayer M | title = After crunching 70k 'trip reports', Mindstate looks to test first AI-derived psychedelic on humans | date = 13 March 2024 | website = Fierce Biotech | url = https://www.fiercebiotech.com/biotech/mindstates-first-ai-derived-psychedelic-heads-clinic | access-date = 10 November 2024 }}</ref><ref name="NewsDesk_2024">{{cite web | title = Mindstate Design Labs AI-Designed Trial Gets FDA Approval | date = 10 September 2024 | website = Microdose | url = https://microdose.buzz/news/mindstate-design-receives-fda-approval/ | access-date = 10 November 2024 }}</ref><ref name="Meissen_2024">{{cite web | vauthors = Meissen A | title = Mindstate Uses AI to Design "Next-Gen" Psychedelics Combined With 5-MeO-MiPT | date = 20 September 2024 | website = Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness | url = https://www.lucid.news/mindstate-uses-ai-to-design-next-gen-psychedelics-combined-with-5-meo-mipt/ | access-date = 10 November 2024 }}</ref> It is under development specifically by Mindstate Design Labs.<ref name="Mullin_2025" /><ref name="AdisInsight" /><ref name="Bayer_2024" /><ref name="NewsDesk_2024" /><ref name="Meissen_2024" /> As of October 2025, the drug is in phase 1 clinical trials in the United States and European Union.<ref name="Mullin_2025" /><ref name="AdisInsight" /><ref name="Bayer_2024" /><ref name="Ovalle_2024">{{cite news | vauthors = Ovalle D, Beard M | title = FDA gives an early nod to psychedelic research | date = 5 September 2024 | newspaper = The Washington Post | url = https://www.washingtonpost.com/politics/2024/09/05/fda-gives-an-early-nod-psychedelic-research/ | access-date = 7 August 2025 }}</ref><ref name="NewsDesk_2024" /><ref name="Ducharme_2024">{{cite magazine | vauthors = Ducharme J | title = Safer Psychedelic Drugs May Be Coming | date = 2 October 2024 | magazine = TIME | url = https://time.com/7027173/new-psychedelic-drug-companies/ | access-date = 7 August 2025 }}</ref> A phase 1 trial was completed in July 2025.<ref name="Mullin_2025" /><ref name="Krol2026" /><ref name="AdisInsight" /> Mindstate Design Labs has developed an artificial intelligence (AI) platform known as Osmanthus to analyze trip reports in order to identify relationships between receptor interactions and psychoactive effects.<ref name="Meissen_2024a">{{cite web | vauthors = Meissen A | title = Mindstate Uses AI to Design "Next-Gen" Psychedelics Combined With 5-MeO-MiPT | date = 20 September 2024 | website = Lucid News | url = https://www.lucid.news/mindstate-uses-ai-to-design-next-gen-psychedelics-combined-with-5-meo-mipt/ | access-date = 10 November 2024 }}</ref><ref name="Nichols_2025">{{cite web | vauthors = Nichols MR | title = The next era of psychedelics may be precision-designed | date = 20 June 2025 | website = Big Think | url = https://bigthink.com/neuropsych/ai-psychedelics-mindstate | access-date = 7 August 2025 }}</ref><ref name="Dimitropoulos_2025">{{cite web | vauthors = Dimitropoulos S | title = Science Has a Powerful New Tool to Unlock the Mysteries of Consciousness—And Even Help You Reach Transcendence | date = 12 June 2025 | website = Popular Mechanics | url = https://www.popularmechanics.com/science/a65023922/designer-psychedelics-consciousness-research/ | access-date = 7 August 2025 | quote = Their first proprietary compound, MOXY, currently in a 52-person Phase I trial, is designed to be just that, says DiNardo: "A sort of 'psychedelic tofu,' a drug that allows moderate cognitive flexibility, but isn't likely to cause awe or ego dissolution." In other words, MOXY acts as a neutral base that's mild on its own, but intended to combine with other compounds to produce fine-tuned mental states. }}</ref><ref name="Houser_2025">{{cite web | vauthors = Houser K | title = Startups Are Trying to Hack Psychedelic Drugs to Make Them Safer | date = 28 May 2025 | website = Futurism | url = https://futurism.com/neoscope/startups-hacking-psychedelic-drugs-safe | access-date = 7 August 2025 }}</ref> Other research of this sort has also been conducted and published by other groups.<ref name="Ballentine_2022">{{cite journal | vauthors = Ballentine G, Friedman SF, Bzdok D | title = Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences | journal = Science Advances | volume = 8 | issue = 11 | date = March 2022 | pmid = 35294242 | pmc = 8926331 | doi = 10.1126/sciadv.abl6989 | article-number = eabl6989 | bibcode = 2022SciA....8L6989B }}</ref> Mindstate Design Labs's platform has processed 70,000{{nbsp}}online trip reports and led to the selection of 5-MeO-MiPT for development.<ref name="Mullin_2025" /><ref name="Meissen_2024a" /><ref name="Nichols_2025" /><ref name="Dimitropoulos_2025" /><ref name="Houser_2025" /> According to its developer, 5-MeO-MiPT is intended as a "neutral base compound" with mild effects on its own for use as a sort of "psychedelic tofu" in combination with other drugs to precisely modulate serotonin receptors and create various unique altered states of consciousness.<ref name="Mullin_2025" /><ref name="Meissen_2024a" /><ref name="Nichols_2025" /><ref name="Dimitropoulos_2025" /><ref name="Houser_2025" />

== References == {{Reflist}}

== External links == * [https://isomerdesign.com/pihkal/explore/5040 5-MeO-MiPT - Isomer Design] * [https://psychonautwiki.org/wiki/5-MeO-MiPT 5-MeO-MiPT - PsychonautWiki] * [https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt.shtml 5-MeO-MIPT - Erowid] * [http://www.erowid.org/library/books_online/tihkal/tihkal40.shtml 5-MeO-MiPT - TiHKAL - Erowid] * [http://tihkal.info/read.php?domain=tk&id=40 5-MeO-MiPT - TiHKAL - Isomer Design] * [https://tripsit.me/factsheets/5-meo-mipt 5-MeO-MiPT - TripSit] * [https://www.youtube.com/watch?v=3WHWmjwfKZM 5-MeO-MiPT: What We Know - The Drug Classroom - YouTube]

Category:5-HT1A agonists Category:5-HT2A agonists Category:5-HT2B agonists Category:5-HT2C agonists Category:Aphrodisiacs Category:David Repke Category:Designer drugs Category:N,N-Dialkyltryptamines Category:Experimental hallucinogens Category:Isopropyl compounds Category:5-Methoxytryptamines Category:Methyl compounds Category:Psychedelic tryptamines Category:Serotonin receptor agonists Category:TiHKAL